CHMP is reviewing avacopan, a drug authorized in the EU for treating adults with severe, active granulomatosis with polyangiitis or microscopic polyangiitis.

EMA begins review of Tavneos, a medicine for rare autoimmune diseases GPA and MPA: Amsterdam, The Netherlands Monday, February 2, 2026, 14:00 Hrs [IST] European Medicines Agencys ...

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2017" report to their offering. Pharmaceutical and Healthcare ...

"EMA will now review all available data to assess whether this emerging information has an impact on the balance of benefits and risks of Tavneos," said the EU regulator. "The agency will then issue a ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) has started a review of Amgen’s Tavneos (avacopan), ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Patients with granulomatosis with polyangiitis and microscopic polyangiitis who lower their ...

The prophylactic efficacy of TMP-SMX was significantly higher in subgroups with baseline lymphopenia, azotemia, microscopic polyangiitis, or relapsed AAV. Prophylactic use of ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Please provide your email address to receive an email when new articles are posted on . New Pan American League of Associations for Rheumatology recommendations include remission maintenance ...

Higher relapse rates were associated with c-ANCA/PR3 positivity and granulomatosis with polyangiitis phenotype. In a retrospective study of patients with antineutrophil cytoplasmic (ANCA)-associated ...